STAMBP and diabetic retinopathy: In diabetic mice, α-MSH treatment suppresses the pathology of diabetic retinopathy by promoting the survival of both ganglion cells and photoreceptors, with the retention of the blood–ocular barrier and the inhibition of the induction of neovascularization [21,24,25,43].